5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Morepen Laboratories Ltd.

•
morepen.comBSE: 500288NSE: MOREPENLAB
Market Cap₹ 6,354 Cr.
Current Price
High / Low₹ 123 / 33
Stock P/E56.7
Book Value₹ 24
Price to Book1.49
Dividend Yield0.17 %
ROCE7.8 %
ROE5.4 %
Face Value₹ 2

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Latest quarter profit grew 570.0% YoY, showing strong momentum
  • Working capital cycle has improved - days down from 151 to 124
  • Company comfortably covers its interest (6.5x coverage)
  • Company maintains a comfortable, low leverage position

CONS

  • Promoter holding has decreased over last 2 years: -2.6pp
  • Company has a low return on equity of 9.5% over last 3 years
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.46x)
  • Free cash flow has been persistently negative
  • Total debt has risen sharply - up 145.2% year on year
  • Valuation is stretched - P/E of 56.7 is well above its own 5-year median (25.8)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.MOREPENLAB115.9545.216353.520.1756.35393.96570.1334.0710.1914.48
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
369381395393386384403382391370458463541
344352344336337341372352372342416440474
Operating Profit25305156494332301928422367
OPM %6.72%7.81%12.95%14.30%12.61%11.22%7.83%7.90%4.84%7.56%9.15%5.04%12.35%
2344355346495
Interest0021111444445
Depreciation5567445128111018
Profit before Tax22274753474330171119312872
Tax %26.99%27.11%25.46%24.19%25.50%25.50%25.31%31.16%28.99%23.81%25.24%27.14%25.16%
Net Profit1620354035322312814242054
0.310.390.690.780.690.600.410.200.150.260.430.370.99

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
5485617177921,1121,4491,3391,5381,5551,6811,831
4875016527281,0001,3201,2621,3761,4011,5691,671
Operating Profit6060656411212977162153112160
OPM %11.05%10.75%9.07%8.14%10.10%8.91%5.77%10.52%9.87%6.67%8.74%
44491220613162324
Interest7422222471617
Depreciation3433383428211822242929
Profit before Tax23262937941266314913889150
Tax %0.00%0.00%0.00%13.74%0.00%19.50%26.65%25.53%26.17%26.00%25.37%
Net Profit23262932941014611110266112
EPS0.520.580.640.722.091.940.922.171.851.21—
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%10.79%16.59%—

COMPOUNDED SALES GROWTH

10 Years:
14%
5 Years:
9%
3 Years:
8%

COMPOUNDED PROFIT GROWTH

10 Years:
15%
5 Years:
-7%
3 Years:
13%

STOCK PRICE CAGR

10 Years:
17%
5 Years:
16%
3 Years:
48%
1 Year:
114%

RETURN ON EQUITY

10 Years:
13%
5 Years:
11%
3 Years:
10%
Last Year:
5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Sep 18

₹ 0.10

Rs.0.2000 per share(10%)Final Dividend

2026

Aug 4

₹ 0.10

Rs.0.2000 per share(10%)Final Dividend

2025

May 12

₹ 0.10

Rs.0.2000 per share(10%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital909090909096102102110110
1341611872173114766787871,0721,133
1701613151921272781173
Trade Payables116165157158192217213267338237
381591721812352238596120255
Total Liabilities5485916196628471,0331,1061,2791,7211,908
191182153135144156171217366403
Capital Work in Progress00002141724288
118118118119119118118126205110
627491132170258211220286154
0000000317294333
Cash & Bank763238674656504647
170211226238346441533325496852
Total Assets5485916196628471,0331,1061,2791,7211,908

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
4961151649-44-86772920
Cash from Investing-15-24-10-12-69-23-36-84-280-119
Cash from Financing-31-38-054766144026097
3-14328-256-69-1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
38.2235.6535.6535.6535.6535.6535.6535.6535.65
1.672.082.221.941.721.621.621.581.46
2.141.691.641.671.501.491.251.251.28
0.010.010.010.010.010.010.010.010.01
57.9660.5660.4760.7261.1161.2161.4661.5061.59

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-07
General Updates

2026-09-07 - Business Update First Phase of Manufacturing Capacity Expansion Completed Ahead of Schedule

2026-09-03
Copy of Newspaper Publication

2026-09-03 - Newspaper publication for completion of dispatch of the notice of 41st AGM and Annual report for the FY 2025-26

2026-09-02
Updates

2026-09-02 - Morepen Laboratories Limited has informed the Exchange regarding 'Morepen Laboratories Limited has informed the Exchange regarding 'Letter To Members, (No E-Mail Id Registered), Comprising Weblink Of The Annual Report : 2025-26'.'.

2026-09-02
Shareholders meeting

2026-09-02 - Morepen Laboratories Limited has informed the Exchange about Shareholders meeting

2026-08-26
Copy of Newspaper Publication

2026-08-26 - Newspaper publication-information relating to 41st Annual General Meeting, Dividend and Record Date

2026-08-06
General Updates

2026-08-06 - Morepen Laboratories Limited has informed the Exchange about allotment of equity shares by Morepen RX Limited, wholly owned subsidiary, to the company

2026-08-05
Copy of Newspaper Publication

2026-08-05 - Morepen Laboratories Limited has informed the Exchange about Newspaper Publication - Financial Results for the quarter ended June 30, 2026

2026-08-04
Monitoring Agency Report

2026-08-04 - Monitoring agency report for the quarter ended June 30, 2026

2026-08-04
General Updates

2026-08-04 - Morepen Laboratories Limited has informed the Exchange about Intimation of 41st Annual General Meeting scheduled to be held on September 26, 2026

News

Recent coverage and analyst commentary for MOREPENLAB

Loading news…

🤖

AI Stock Analyst

Morepen Laboratories Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login